Observational studyJournal of the American Heart Association2026
Edaravone Dexborneol in Large Ischemic Stroke: Real-World Experience from a Multicenter Study in China.
Observational study in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05644223 (Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke: a Multicenter, Prospective, Patient-centered, Real-world Cohort Study
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Edaravone dexborneol in acute ischemic stroke: a systematic review and meta-analysis of randomized trials with clinical and thrombectomy-specific subgroup analyses.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Lipid accumulation product and its association between new onset stroke among middle age and elderly population.BMC cardiovascular disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEdaravone dexborneol, a novel neuroprotective agent with combined antioxidant and anti-inflammatory properties, has demonstrated significant improvement in 90-day functional outcomes for patients with acute ischemic stroke. This study aimed to evaluate the outcomes of edaravone dexborneol in patients with acute ischemic stroke with large infarct core.
methodsThis prospective, multicenter, parallel-group, real-world cohort study was conducted between December 2022 and October 2023 across 72 centers in China. Participants were categorized into an exposed group (receiving edaravone dexborneol 37.5 mg/dose every 12 hours for 14 days) and an unexposed group (not receiving edaravone dexborneol). Propensity score matching (1:1) was used to balance baseline characteristics, and clinical outcomes were compared between the groups. The primary efficacy outcome was the proportion of patients achieving a modified Rankin Scale score of ≤2 at 90 days.
resultsAfter matching, the 90-day modified Rankin Scale ordinal shift was significantly better in the edaravone dexborneol group compared with the unexposed group (median: 2 [interquartile range, 1-4.5] versus 3 [interquartile range, 1-5]; unadjusted odds ratio [OR], 1.90 [95% CI, 1.04-3.46];
conclusionsIn patients with acute ischemic stroke with large infarct core, edaravone dexborneol improved the likelihood of achieving favorable functional outcomes at 90 days. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05644223.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.